Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovail, a specialty pharmaceutical company, has announced that its subsidiary, Biovail Laboratories International, has entered into a supply agreement with Sanofi Aventis US for the marketing and distribution of Aplenzin in the US and Puerto Rico.
Subscribe to our email newsletter
Aplenzin, which was approved by the FDA in April 2008, is indicated for the treatment of major depressive disorder. Biovail anticipates that Sanofi Aventis US will launch the 348mg and 522mg dosage strengths of Aplenzin in the first quarter of 2009.
Under the terms of the agreement, Biovail will manufacture, supply and sell Aplenzin to Sanofi Aventis US at contractually determined prices, which will be based on Sanofi Aventis US’s net selling price. Biovail’s supply price will range from 25% to 35% of net sales, depending on the level of net sales of Aplenzin. Other financial terms were not disclosed.
Bill Wells, Biovail’s CEO and president, said: “We are pleased to have entered into this partnership with Sanofi Aventis US. The support of their world-class marketing organization bodes well for a successful launch for Aplenzin.”